Navigation Links
Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
Date:8/10/2009

PALO ALTO, Calif., Aug. 10, 2009 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial, run in centers in Australia and New Zealand, will investigate the antiviral effect of clemizole monotherapy in the absence of interferon.

CLEAN-1 will evaluate the safety and antiviral activity of clemizole, a first generation antihistamine, in 28 days of oral therapy in treatment-naive patients infected with HCV genotypes 1 and 2. This direct antiviral study represents an important first step in evaluating the therapeutic potential of inhibiting a new target in HCV -- small molecule inhibition of the interaction between NS4B and HCV-RNA that is required for HCV replication.

"This proof of concept study is an important first step in our comprehensive development strategy for clemizole and newly discovered NS4B-RNA binding inhibitors for the treatment of HCV," said David Cory, President and CEO of Eiger. "Inhibiting the NS4B-RNA interaction represents an exciting new approach toward developing interferon-free, virus-specific agents to treat HCV."

Eiger BioPharmaceuticals recently announced the acquisition of the exclusive license to this novel HCV technology, discovered in the labs of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues. Clemizole targets a non-structural protein found in the HCV genome, NS4B, which binds to HCV-RNA and is required for virus replication. Disrupting the function of this protein represents a new approach to treat HCV infection and may be associated with less drug resistance than polymerase and protease inhibitors in development.

About NS4B and Clemiz
'/>"/>

SOURCE Eiger BioPharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
2. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
3. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
5. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
7. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
8. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
9. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
10. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
11. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 EHE International, the recognized leader in preventive ... today announced that David Abrams M.D . in ... preventive care center. Through David Abrams M.D ., EHE ... have greater access to EHE,s preventive care programs to help ... to add Dr. Abrams M.D. to its growing private provider ...
(Date:9/16/2014)... Sept. 16, 2014  Advanced Medical Isotope ... development company engaged primarily in the development ... diagnostic and therapeutic applications, today announced that ... to its brachytherapy products.  AMIC,s rights for ... license from Battelle, under which AMIC exclusively ...
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
Breaking Medicine Technology:EHE International Certifies David Abrams M.D. as Its Newest Partner 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2
... , , JERUSALEM, Israel, January 11 ... systems, today announced that it has filed two registration,statements on ... One registration statement relates to a proposed ... and warrants to purchase 12,million shares of common stock, as ...
... , SAN JOSE, Calif., Jan. 11 Finesse Solutions, ... life sciences process applications, announced the production release of ... oxygen or pH and process temperature, and TruTorr headspace ... accuracy, lifetime, and ease of use. It is available ...
Cached Medicine Technology:Oramed Pharmaceuticals Announces Filing of Two Registration Statements 2Oramed Pharmaceuticals Announces Filing of Two Registration Statements 3Single-Use Sensor Product Family Enters High Volume Production 2
(Date:9/16/2014)... Former Major League Baseball relief pitcher Kent Tekulve ... surgery at Allegheny General Hospital (AGH) on Friday, September ... 16-year baseball career with the Pittsburgh Pirates and now ... Pittsburgh, was discharged home on Friday, September 12, according ... of AGH’s heart transplant program. , “Mr. Tekulve continues ...
(Date:9/16/2014)... Dennis Thompson HealthDay Reporter ... leading to strong heart fitness can delay a man,s onset ... new study suggests. Blood pressure naturally increases as people ... But men with strong cardio-fitness don,t start drifting toward high ... sedentary men usually experience the early signs of high blood ...
(Date:9/16/2014)... -- Illegal drug use among teens in the United States ... Encouragingly, the new study also found that alcohol ... young people between the ages of 12 and 17 also ... 70,000 people aged 12 and older across the United States ... problems among this age group also dropped from 8.9 percent ...
(Date:9/16/2014)... mathematical model that replicates Ebola outbreaks can no longer ... current epidemic, finds research conducted by the University of ... Mathematics Institute, developed a model that incorporated data from ... , The research, titled Epidemiological Dynamics of Ebola Outbreaks ... applying the available data from the ongoing 2014 outbreak ...
(Date:9/16/2014)... make discoveries everyday, but that doesn,t mean the findings ... for example, the neonatal mortality rate is 10 times ... found that applying an inexpensive topical solution of chlorhexidine ... mortality rate by 24 percent, many Indian parents did ... is not that we don,t have solutions to solve ...
Breaking Medicine News(10 mins):Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 2Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 3Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 2Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 3Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2Health News:Ebola outbreak 'out of all proportion' and severity cannot be predicated 2Health News:Pairing social networks with social motives to close the science gap 2Health News:Pairing social networks with social motives to close the science gap 3
... and longevity to health status and quality of life. Researchers ... longer, but the quality of life in later years must// ... benefits of staying physically active in your later years. The ... to perform their daily activities easier later in life. ...
... for a cure for diabetes. A new study done in ... insulin producing //pancreatic islet cells. This could lead to a ... research is a follow up to the 2001 report of ... The new research focuses on the biological mechanism behind that ...
... a deterioration of the retina, is the number one cause ... significantly // reduce the number of people with vision loss ... ,A couple of years ago, researchers conducted a ... vitamins C, E, and beta carotene, along with zinc oxide ...
... lifestyle changes and medication can prevent or delay the onset ... used to identify high-risk individuals for diabetes, but the test ... of risk //factors known as metabolic syndrome is able to ... ,Metabolic syndrome has been shown to lead to the ...
... eat play a role in whether you’ll end up with ... women between //ages 20 and 40 for one year. Their ... at least eight servings of fruits or vegetables a day ... than those who ate their usual diets. ,The ...
... a historic vote Friday night on a bill that would ... // of the politically popular entitlement program in its 38-year ... have lined up in our favor," House Speaker Dennis Hastert ... time is upon us. It's now or never." ...
Cached Medicine News:Health News:Predictors for Type 2 Diabetes 2Health News:House heads for Medicare drug vote, 2Health News:House heads for Medicare drug vote, 3
... onsite test! QuickScreen multi-panel dip cards offer ... your choice of any conceivable combination of ... flexibility for your drug testing program. Just ... the built-in timer tells you when to ...
... Screen Tests are available in 14 configurations ... Designed using Microgenics Antibody Technology, the SureStep™ ... of care immunoassay targeted to detect MDMA ... and MDEA but no cross-reactivity to any ...
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
... are highly accurate in detecting the presence of ... by GC/MS testing. This assay provides a preliminary ... as GC/MS) must be used in order to ... applied to any drug of abuse test result, ...
Medicine Products: